About Cullgen
Cullgen is a company based in San Diego (United States) founded in 2018 by Yue Xiong and Jian Jin was acquired by Gyre Therapeutics in March 2026.. Cullgen has raised $121 million across 4 funding rounds from investors including Gyre Therapeutics, GNI Group and Sincere Capital.
- Headquarter San Diego, United States
- Founders Yue Xiong, Jian Jin
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cullgen Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$121 M (USD)
in 4 rounds
-
Latest Funding Round
$40 M (USD), Series B
May 08, 2023
-
Investors
Gyre Therapeutics
& 12 more
-
Employee Count
Employee Count
-
Acquired by
Gyre Therapeutics
(Mar 02, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Cullgen
Cullgen has successfully raised a total of $121M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $40.0M
-
First Round
First Round
(02 Mar 2018)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series B - Cullgen | Valuation | CICC Capital | |
| Feb, 2021 | Amount | Series B - Cullgen | Valuation | 3E BioVentures | |
| Apr, 2019 | Amount | Series A - Cullgen | Valuation | Highlight Capital , Sequoia Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cullgen
Cullgen has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Gyre Therapeutics, GNI Group and Sincere Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage US tech investments are managed by Voyager Capital.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in technology and biotech sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cullgen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cullgen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cullgen Comparisons
Competitors of Cullgen
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cullgen
Frequently Asked Questions about Cullgen
When was Cullgen founded?
Cullgen was founded in 2018.
Where is Cullgen located?
Cullgen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Cullgen?
Ying Luo is the current CEO of Cullgen.
Is Cullgen a funded company?
Cullgen is a funded company, having raised a total of $121M across 4 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Mar 02, 2018.
What does Cullgen do?
Cullgen is developing small molecules for the treatment of cancer, inflammatory, and autoimmune diseases. The company has developed uSMITE, a protein degradation technology. The company is developing drugs using its technology which is based on ubiquitin-mediated small molecule induced target elimination. The candidate is targeting the ubiquitin-proteasome system. It is in the preclinical stage as of Feb 2019.
Who are Cullgen's investors?
Cullgen has 13 investors. Key investors include Gyre Therapeutics, GNI Group, Sincere Capital, Voyager Capital, and Wuxi Venture Capital Group.